Source European Commission Atherosclerosis is a common, potentially serious condition caused by a build-up of fatty material in the lining of the artery walls. It can lead to coronary artery disease, stroke or kidney problems, and existing treatments tend to be only short-term fixes. In response to this public health challenge, EU-funded project THE GRAIL
Transaction allows Santhera to advance its long-term growth strategy by focusing on the development of its clinical-stage neuromuscular and pulmonary programs Santhera Pharmaceuticals announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international researchfocused healthcare group (Chiesi Group), under which Chiesi Group will in-license Raxone® for the treatment of LHON
Future topics To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes information on possible future topics well in advance of the official Call launch. To ensure you get the latest information on forthcoming Calls, sign up to our newsletter, follow us on Twitter, or join our LinkedIn group.
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation Verily, an Alphabet company, today announced strategic alliances with Novartis, Otsuka, Pfizer Inc. and Sanofi to develop digitally innovative, patient-centered clinical research programs using Project Baseline’s evidence generation platform and tools. The Baseline Platform is designed
In light of additional data from ongoing trials of onasemnogene abeparvovec (Zolgensma®, Novartis/AveXis), as well as the treatment’s final FDA label and just-announced launch price, the Institute for Clinical and Economic Review (ICER) today published an addendum to its Final Evidence Report on treatments for spinal muscular atrophy (SMA). Since the publication of ICER’s Final Evidence Report on
CEO Steven Collens shares his thoughts on what the healthcare system will look like 20 years from now. One day, a doctor will reach out to you before you even know you’re sick. That’s the future we see coming to life in the technologies emerging from the healthcare innovation community. One of the most interesting
In the paper “Three‐Dimensional Bioprinting in Regenerative Medicine: Reality, Hype, and Future,” authors Anthony Atala and Gabor Forgacs explore some necessary topics within 3D printing and bioprinting. The technology has brought forth incredible innovation capable of transforming manufacturing, design mechanisms, and offering never dreamed of self-sustainability that could be even more useful in the future
Boston University neuroscientist shows that stimulating different parts of the brain can dial up or down a specific memory’s emotional oomph What if scientists could manipulate your brain so that a traumatic memory lost its emotional power over your psyche? Steve Ramirez (CAS’10), a Boston University neuroscientist fascinated by memory, believes that a small structure in the
Source STAT he Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most expensive drug in the world. Known as Zolgensma, the gene therapy treats children under 2 years of age with spinal muscular atrophy, an
Source Nature One day before the last parliament dissolved, on 17 April, negotiators signed off on the general outlines of the union’s next giant research programme, known as Horizon Europe, which runs from 2021 to 2027. The EU’s much sought after multi-year research programmes support academic and commercial research across its 28 member states and
